English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims  Both fasting ( FPG ) and postprandial plasma glucose ( PPG ) contribute to HbA 1c  levels. We investigated the relationship between achievement of American Diabetes Association ( ADA ) and American Association of Clinical Endocrinologists ( AACE ) recommended  FPG  and/or  PPG  targets and glycaemic efficacy outcomes in two trials.    Methods  In this  post hoc  analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan‐O ( NCT  02058147) and LixiLan‐L ( NCT  02058160) trials were evaluated to compare the relationship between achievement of society‐recommended  FPG  and/or  PPG  targets and efficacy (HbA 1c  change, HbA 1c  goal attainment, weight change) and safety outcomes in the treatment groups.    Results  Across treatment arms,  iG larLixi achieved the highest proportion of participants meeting both  ADA ‐ and  AACE ‐recommended  FPG  and  PPG  targets at study end in both trials. A higher proportion of participants in the  iG larLixi (fixed‐ratio combination of insulin glargine and lixisenatide) vs. insulin glargine alone or lixisenatide alone treatment arms achieved HbA 1c  goals ( P  < 0.001 for overall comparisons), irrespective of  ADA ‐ or  AACE ‐defined targets. Hypoglycaemia rates [any, documented symptomatic (plasma glucose ≤ 3.9 mmol/l), and clinically important (plasma glucose < 3.0 mmol/l)] were low across all groups. Participants treated with  iG larLixi tended to show weight loss or less weight gain compared with participants receiving insulin glargine alone. No differences were observed in average daily basal insulin dose at week 30 between the two treatment arms or across the different  FPG  and  PPG  target groups.    Conclusion  Insulin glargine and lixisenatide as a fixed‐ratio combination resulted in more participants reaching both  FPG  and  PPG  targets, leading to better HbA 1c  target attainment.

diabetic medicine

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a  post hoc  analysis of the LixiLan‐O and LixiLan‐L trials